My name is Shibli Atrash. I'm a physician at the Levine Cancer Institute, Charlotte, North Carolina. Dr. Hayra is presenting the results of a retrospective multi-center clinical trial, retrospective chart review of talcuitum abuse in real world multiple myeloma patients with relapsed refractory disease. She reports the results of talcuitum abuse as a single agent and overall the responses were around 65% in line with the previously published data. Also we went through adverse events which seem to be very similar to what have been previously published. It's important to note that as expected patients with extremidular disease did not have similar overall response rates to patients without extremidular disease. We still see response in both patients but the responses in extremidular disease were around 30%. Also patients who received or were refractory to prior monoclonal antibodies did not have as good overall response rates to those patients without prior exposure to monoclonal antibodies. Overall the majority of patients did not meet the eligibility criteria for previously published study for talcuitum AB. However, the overall response rates remained similar confirming that this trial represents the similar outcome of the real world patients to what have been previously published about talcuitum AB treatment. Also Dr. Hayra published another abstract about the utility of talcuitum AB as bridging to CAR T therapy. As we know CAR T therapies that are approved for multiple myeloma are VCMA targeted and most of the time we need to use bridging therapy to decrease the disease burden and decrease the CRS and ICANS when we administer CAR T's. And talcuitum AB is a non-TGPCR CRT5T to targets which is different than the VCMA target and it's very useful as a bridging treatment. We see the results of 13 patients who were successfully bridged with talcuitum AB prior to receiving CAR T therapy allowing for talcuitum AB to be an option for bridging for patients who are going for VCMA CAR T therapy.
HealthTree • October 9, 2024